Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9784MR)

This product GTTS-WQ9784MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9784MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ302MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ1050MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ14296MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ2247MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ9308MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ7724MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ14767MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ7232MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW